Essentials of SGLT2 Inhibitors in Diabetes - Fisher, Miles;McKay, Gerard
37,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Written by experts in the field, this clinical handbook explores the novel SGLT2 drug class for the treatment of diabetes. This book includes evidence-based guidelines, major clinical trials, and a discussion of treatment options currently available, as well as those currently in development. Essentials of SGLT2 Inhibitors is an ideal educational resource for busy medical professionals who need to stay up-to-date with diabetes treatment advances in order to provide the best possible clinical care for their patients.

Andere Kunden interessierten sich auch für
Produktbeschreibung
Written by experts in the field, this clinical handbook explores the novel SGLT2 drug class for the treatment of diabetes. This book includes evidence-based guidelines, major clinical trials, and a discussion of treatment options currently available, as well as those currently in development. Essentials of SGLT2 Inhibitors is an ideal educational resource for busy medical professionals who need to stay up-to-date with diabetes treatment advances in order to provide the best possible clinical care for their patients.
Autorenporträt
Professor Miles Fisher graduated from the University of Glasgow in 1979, where he received his MD in 1988 for his thesis on 'Evidence for a Diabetic Cardiopathy.' He has been a consultant physician at Glasgow Royal Infirmary since 2001. In 2010, he was made an Honorary Professor at the University of Glasgow. He was a Vice-President (Medical) of the Royal College of Physicians and Surgeons of Glasgow from 2011-2014. Professor Fisher is the current President of the Scottish Society of Physicians. He interests include diabetes and the heart, hypoglycemia, and new treatments for diabetes, and he is the author or co-author of over 70 original papers, over 60 review articles, and over 40 book chapters. He was on the steering committee of the DIGAMI 2 study as the Scottish coordinator, as well as an events adjudicator for the HOPE and HOPE-TOO studies, and is currently an events adjudicator for the ACE Trial. Professor Gerald (Gerry) McKay studied medicine at the University of Glasgow with subsequent training in the west of Scotland before undertaking specialty training in clinical pharmacology and therapeutics in Newcastle upon Tyne. Additional specialty training included specific training in diabetes and cardiovascular risk management. As an Association of the British Pharmaceutical Industry (ABPI)-sponsored trainee, Professor McKay spent a year in industry with Pfizer gaining experience in all aspects of drug development. He also had a secondment to the National Institute for Health and Clinical Excellence (NICE).  After 3 years as a consultant in a busy district general hospital, in 2007 Professor McKay became a Consultant Physician and Clinical Pharmacologist at Glasgow Royal Infirmary. He contributes to the provision of diabetes care in the north east of Glasgow with a specialist interest in type 2 diabetes and diabetic nephropathy, as well as an interest in safe and rational prescribing. He has considerable commitment to undergraduate and postgraduate education at the University of Glasgow and University of Strathclyde where he holds honorary positions. Additionally, he is Vice Chair of NHS Greater Glasgow and Clyde's Area Drug and Therapeutics committee and served for 7 years on the New Drugs Committee of the Scottish Medicines Consortium. Professor McKay is the co-editor of a major undergraduate textbook on clinical pharmacology and has published numerous papers in the field of diabetes and therapeutics. Jenna L Cowan, MbChB, BSc (Med Sci), MRCP has been a specialty registrar in Diabetes and Endocrinology in the West of Scotland Deanery since 2008. She qualified from the University of Glasgow in 2004 and is currently completing her final specialty training at the Queen Elizabeth University Hospital in Glasgow. Her clinical interests include genetic and gestational diabetes.